Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

ONCY : 1.1400 (-3.39%)
ONC.TO : 1.60 (-3.61%)
EXEL : 34.29 (+0.50%)
MRTX : 58.70 (-0.17%)
LLY : 806.14 (-1.56%)
PNT : 12.50 (+0.16%)
3 No-Brainer Stocks to Buy With $500 Right Now

A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts.

NEE : 78.37 (+1.32%)
NEP : 20.19 (+4.88%)
BMY : 55.45 (+2.08%)
MRTX : 58.70 (-0.17%)
MO : 53.88 (+0.02%)
Mirati: Q3 Earnings Snapshot

Mirati: Q3 Earnings Snapshot

MRTX : 58.70 (-0.17%)
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...

AAPL : 222.01 (-0.40%)
NYT : 52.45 (-7.71%)
ONCY : 1.1400 (-3.39%)
ONC.TO : 1.60 (-3.61%)
MACK : 15.13 (unch)
INCY : 75.75 (-0.50%)
MRTX : 58.70 (-0.17%)
BNTX : 108.97 (-2.25%)
3 Things About Bristol Myers Squibb That Smart Investors Know

The stock is down this year, but will its struggles fade into the rearview mirror?

BMY : 55.45 (+2.08%)
MRTX : 58.70 (-0.17%)
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2...

MRTX : 58.70 (-0.17%)
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race

Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to buy...

DTC.CN : 0.6200 (+12.73%)
BMY : 55.45 (+2.08%)
MRTX : 58.70 (-0.17%)
LLY : 806.14 (-1.56%)
PNT : 12.50 (+0.16%)
DTCFF : 0.4140 (-5.07%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNSL, PCTI, SP, MRTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CNSL : 4.64 (unch)
PCTI : 6.99 (-0.14%)
SP : 53.99 (+0.04%)
MRTX : 58.70 (-0.17%)
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...

DTC.CN : 0.6200 (+12.73%)
MGNX : 3.70 (-4.39%)
IOVA : 11.44 (+2.23%)
MRTX : 58.70 (-0.17%)
MRSN : 1.8400 (+1.10%)
DTCFF : 0.4140 (-5.07%)
LLY : 806.14 (-1.56%)
PFE : 27.76 (-1.17%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWLI, MRTX, SLGC, PNT

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

NWLI : 499.98 (+0.08%)
MRTX : 58.70 (-0.17%)
SLGC : 2.10 (-4.55%)
PNT : 12.50 (+0.16%)

Barchart Exclusives

Is This High-Yield Dividend Stock a Buy After Earnings?
This pharmaceutical giant's Q3 numbers came in ahead of Street estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar